Shanghai Henlius Biotech, Inc.

Shanghai Henlius Biotech, Inc. is a global, innovation-driven biopharmaceutical company dedicated to providing high-quality, affordable biologic therapies to patients worldwide. The company's mission is to improve patients' lives through technical innovation and operational excellence in protein therapeutics. Headquartered in Shanghai, China, Henlius operates an integrated biopharmaceutical platform encompassing global research and development, clinical operations, regulatory affairs, manufacturing, and commercialization.

Henlius focuses on major disease areas, including oncology, autoimmune diseases, and ophthalmic diseases. Its product portfolio includes 10 approved products globally, such as biosimilars like HANLIKANG (rituximab), HANQUYOU (trastuzumab), HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), BILDYOS® and BILPREVDA® (denosumab), and innovative therapies like HANSIZHUANG (serplulimab), an anti-PD-1 monoclonal antibody. The company maintains a robust pipeline with over 50 early-stage innovative assets, including monoclonal antibodies, multispecific antibodies, and antibody-drug conjugates (ADCs), with more than 30 clinical studies ongoing globally.

Led by CEO Dr. Jason Zhu, Henlius has evolved into a globally operating biopharmaceutical company with a strong international footprint. The company is executing a "Globalisation 2.0" strategy, aiming to achieve over 20 product approvals globally by 2030, with more than 15 in the U.S. and European markets. Recent developments include regulatory approval from China's NMPA for Phase 1 clinical trials of HLX37 and HLX43 in advanced solid tumors. Its core product, serplulimab, continues to gain global commercial momentum, with approvals in Europe and various emerging markets for multiple indications.